Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Marc Goodman
LP
Marc Goodman
Leerink Partners
Wall Street Analyst
★★★★☆
#561
on 13Foresight · ranked by our own returns
61%
Success Rate
+54.8%
Average Return
30 of 49 calls profitable · +42.5% vs benchmark
📈 Across the calls we could measure, roughly 61% of Marc Goodman's ratings turned a profit when each position was held for 1 year — averaging +54.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

62 Buy 8 Hold 0 Sell
Marc's Stock Coverage 52 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
STOK
Stoke Therapeutics
 Jun 02, 2026 BUY Strong Buy
+25.1% avg upside
18 analysts
 — +4.6%
SPTX
Seaport Therapeutics, Inc.
 May 27, 2026 BUY Strong Buy
+95.4% avg upside
4 analysts
$35.00
92.71% Upside
 ·
ACIU
AC Immune SA
 Apr 07, 2026 BUY Strong Buy
+233.3% avg upside
5 analysts
 — -10.3%
ALKS
Alkermes
 Mar 31, 2026 HOLD Strong Buy
-17.5% avg upside
34 analysts
 — +28.2%
SGP
SpyGlass Pharma
 Mar 03, 2026 BUY Strong Buy
+141.9% avg upside
5 analysts
$42.00
124.59% Upside
 -30.1%
MANE
Veradermics, Incorporated
 Mar 02, 2026 BUY Strong Buy
+31.9% avg upside
6 analysts
$75.00
20.15% Downside
 ·
NMRA
Neumora Therapeutics, Inc.
 Jan 11, 2026 BUY Buy
+422.4% avg upside
11 analysts
$8.00
429.82% Upside
 -17.1%
BHVN
Biohaven Ltd.
 Dec 25, 2025 BUY Strong Buy
+87.5% avg upside
25 analysts
$15.00
10.62% Upside
 +21.7%
MPLT
MapLight Therapeutics, Inc.
 Nov 21, 2025 BUY Strong Buy
+32.5% avg upside
11 analysts
$30.00
4.18% Upside
 +94.1%
OVID
Ovid Therapeutics
 Nov 17, 2025 BUY Strong Buy
+108.4% avg upside
17 analysts
$5.00
120.30% Upside
 +102.3%
BLTE
Belite Bio, Inc. ADR
 Oct 15, 2025 BUY Strong Buy
+25.0% avg upside
10 analysts
$85.00
41.88% Downside
 +70.1%
OCS
Oculis Holding
 Oct 09, 2025 BUY Strong Buy
+241.9% avg upside
11 analysts
$50.00
345.68% Upside
 -45.8%
ACAD
ACADIA Pharmaceuticals
 Oct 07, 2025 BUY Strong Buy
+66.0% avg upside
42 analysts
$30.00
38.70% Upside
 +0.3%
AMLX
Amylyx Pharmaceuticals Inc
 Oct 07, 2025 BUY Strong Buy
+46.8% avg upside
13 analysts
$20.00
27.55% Upside
 +13.9%
EOLS
Evolus
 Oct 07, 2025 BUY Strong Buy
+116.3% avg upside
9 analysts
 — +7.7%
AXSM
Axsome Therapeutics
 Oct 07, 2025 BUY Strong Buy
-10.5% avg upside
28 analysts
 — +112.3%
XENE
Xenon
 Oct 07, 2025 BUY Strong Buy
+19.0% avg upside
28 analysts
 — +33.8%
JAZZ
Jazz Pharmaceuticals
 Oct 07, 2025 BUY Strong Buy
-1.8% avg upside
35 analysts
$215.00
4.23% Downside
 +67.9%
BIIB
Biogen
 Oct 07, 2025 BUY Strong Buy
+25.1% avg upside
51 analysts
 — +30.5%
LBRX
LB Pharmaceuticals, Inc.
 Oct 06, 2025 BUY Strong Buy
+50.1% avg upside
7 analysts
$34.00
13.26% Upside
 +84.2%
NBIX
Neurocrine
 Sep 23, 2025 BUY Strong Buy
+7.8% avg upside
37 analysts
 — +9.1%
KLRS
Kalaris Therapeutics
 Sep 16, 2025 BUY Buy
+170.8% avg upside
13 analysts
$20.00
323.70% Upside
 -2.2%
DNLI
Denali Therapeutics
 Aug 13, 2025 BUY Strong Buy
+60.2% avg upside
24 analysts
$40.00
71.60% Upside
 +48.1%
ALDX
Aldeyra Therapeutics
 Aug 12, 2025 BUY Strong Buy
+716.1% avg upside
21 analysts
$10.00
410.25% Upside
 -68.7%
DFTX
Definium Therapeutics
 Aug 01, 2025 BUY Strong Buy
+45.0% avg upside
20 analysts
$20.00
18.30% Downside
 +189.5%
LENZ
LENZ Therapeutics
 Aug 01, 2025 BUY Buy
+281.4% avg upside
17 analysts
$36.00
485.46% Upside
 -77.2%
RLMD
Relmada Therapeutics
 May 13, 2025 HOLD Buy
+106.4% avg upside
15 analysts
 — +1820.5%
OPTEY
Opthea Limited Sponsored ADR
 Mar 26, 2025 HOLD Hold
+37213.4% avg upside
7 analysts
$1.00
4875.16% Upside
 ·
JNJ
Johnson & Johnson
 Jan 13, 2025 BUY Strong Buy
-3.6% avg upside
36 analysts
 — +52.4%
CLYM
Climb Bio
 May 12, 2023 BUY Strong Buy
+57.9% avg upside
18 analysts
$4.00
65.04% Downside
 +164.4%
ALLO
Allogene Therapeutics
 Jan 24, 2023 BUY Strong Buy
+662.8% avg upside
28 analysts
$24.00
1100.02% Upside
 -60.2%
IRON
Disc Medicine
 Jul 11, 2022 HOLD Strong Buy
+20.3% avg upside
21 analysts
$20.00
71.83% Downside
 -4.0%
CALC
CalciMedica
 Jul 11, 2022 HOLD Buy
+3672.8% avg upside
9 analysts
$70.00
9166.60% Upside
 -38.4%
DC
Dakota Gold Corp
 Jun 27, 2022 HOLD Strong Buy
+130.8% avg upside
5 analysts
 — ·
CRC
California Resources Corp
 May 03, 2022 BUY Strong Buy
+34.1% avg upside
19 analysts
 — -3.8%
A
Agilent
 May 13, 2021 BUY Strong Buy
+3.9% avg upside
32 analysts
$25.00
80.25% Downside
 -7.7%
APA
APA
 May 04, 2021 BUY Hold
+12.2% avg upside
41 analysts
 — +126.3%
CRL
Charles River Labs
 Apr 05, 2021 BUY Strong Buy
+12.0% avg upside
34 analysts
$31.00
83.32% Downside
 -3.1%
VRTX
Vertex Pharmaceuticals
 Mar 19, 2019 HOLD Strong Buy
-2.7% avg upside
61 analysts
 — +18.7%
REGN
Regeneron
 Nov 12, 2018 BUY Strong Buy
+26.9% avg upside
57 analysts
$473.00
22.38% Downside
 +0.5%
BMY
Bristol-Myers Squibb
 May 21, 2018 HOLD Buy
+9.1% avg upside
42 analysts
$57.00
5.51% Upside
 -6.4%
VTRS
Viatris
 Mar 01, 2018 BUY Buy
+48.2% avg upside
21 analysts
$54.00
251.36% Upside
 -32.5%
PFE
Pfizer
 Jan 31, 2018 BUY Buy
+34.1% avg upside
45 analysts
$42.00
66.61% Upside
 +19.7%
TEVA
Teva Pharmaceutical
 Dec 18, 2017 HOLD Buy
-6.8% avg upside
39 analysts
$20.00
36.48% Downside
 -8.2%
MRK
Merck & Company
 Oct 30, 2017 BUY Strong Buy
+10.7% avg upside
43 analysts
$67.00
41.19% Downside
 +37.5%
ABBV
AbbVie
 Oct 13, 2017 HOLD Buy
+2.8% avg upside
43 analysts
$95.00
56.11% Downside
 +3.9%
PRGO
Perrigo Company
 Oct 05, 2017 BUY Buy
+565.5% avg upside
20 analysts
$98.00
856.11% Upside
 -16.8%
LLY
Eli Lilly & Co
 Jul 26, 2017 HOLD Strong Buy
-10.5% avg upside
47 analysts
$85.00
92.18% Downside
 +19.5%
AMRX
Amneal Pharmaceuticals
 Nov 10, 2016 SELL Strong Buy
+5.6% avg upside
18 analysts
$12.00
26.02% Downside
 ·
GILD
Gilead Sciences
 Nov 02, 2016 BUY Strong Buy
-4.8% avg upside
66 analysts
$118.00
4.71% Downside
 +4.7%
IRWD
Ironwood Pharma
 Jun 14, 2016 SELL Hold
+235.8% avg upside
23 analysts
$8.00
126.00% Upside
 -37.8%
TSE:BHC
Bausch Health Companies
 Mar 21, 2016 BUY Buy
+783.6% avg upside
29 analysts
 — ·
🔒 47 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Marc Goodman — Frequently Asked Questions
How accurate are Marc Goodman's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Marc's ratings were profitable over a one-year hold, with an average return of +54.8% per rating, or +42.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Marc ranked on 13Foresight?
Marc Goodman is currently ranked #561 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Marc cover?
Marc most recently has ratings on STOK, SPTX, ACIU, ALKS, SGP, MANE, NMRA, BHVN, MPLT, OVID, BLTE, OCS and 40 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.